Fortress Biotech (STU:CNB1) Cyclically Adjusted PS Ratio: (As of Aug. 15, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:CNB1 Fortress Biotech Inc STU:CNB1
45 GF Score
Price €1.93
GF Value €0.86
! 6 Warning Signs
View Full Analysis

What is Fortress Biotech Cyclically Adjusted PS Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PS Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Fortress Biotech  (STU:CNB1) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Fortress Biotech Cyclically Adjusted PS Ratio Related Terms


Fortress Biotech Cyclically Adjusted PS Ratio Historical Data

* Premium members only.

The historical data trend for Fortress Biotech's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fortress Biotech Cyclically Adjusted PS Ratio Chart

Fortress Biotech Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 3.95 0.94 0.28 0.20 0.35

Fortress Biotech Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.18 0.35 0.35 0.26 0.29

STU:CNB1 vs PMN, VANI, SEER: Cyclically Adjusted PS Ratio Comparison

For the Biotechnology subindustry, Fortress Biotech's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Fortress Biotech Cyclically Adjusted PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Fortress Biotech's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Fortress Biotech's Cyclically Adjusted PS Ratio falls into.


STU:CNB1
45GF Score
Fortress Biotech Inc STU:CNB1
Cyclically Adjusted PS Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fortress Biotech Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Fortress Biotech's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Fortress Biotech's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.523/333.9520*333.9520
=0.523

Current CPI (Jun. 2026) = 333.9520.

Fortress Biotech Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.325 241.428 0.450
201612 4.462 241.432 6.172
201703 15.525 243.801 21.266
201706 16.693 244.955 22.758
201709 14.489 246.819 19.604
201712 -35.214 246.524 -47.702
201803 1.689 249.554 2.260
201806 2.017 251.989 2.673
201809 1.484 252.439 1.963
201812 2.750 251.233 3.655
201903 1.347 254.202 1.770
201906 2.285 256.143 2.979
201909 2.341 256.759 3.045
201912 2.518 256.974 3.272
202003 2.762 258.115 3.574
202006 1.838 257.797 2.381
202009 1.586 260.280 2.035
202012 2.124 260.474 2.723
202103 1.806 264.877 2.277
202106 2.744 271.696 3.373
202109 3.305 274.310 4.024
202112 2.901 278.802 3.475
202203 3.778 287.504 4.388
202206 3.020 296.311 3.404
202209 642.038 296.808 722.386
202212 2.102 296.797 2.365
202303 1.709 301.836 1.891
202306 2.175 305.109 2.381
202309 4.342 307.789 4.711
202312 1.701 306.746 1.852
202403 0.699 312.332 0.747
202406 0.755 314.175 0.803
202409 0.669 315.301 0.709
202412 0.555 315.605 0.587
202503 0.460 319.799 0.480
202506 0.477 322.561 0.494
202509 0.454 324.800 0.467
202512 0.443 324.054 0.457
202603 0.447 330.213 0.452
202606 0.523 333.952 0.523

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Fortress Biotech (STU:CNB1) Overvalued in 2026?

Based on GuruFocus' analysis, Fortress Biotech stock appears to be overvalued. The current stock price of €1.93 is trading 124.4% above its estimated GF Value™ of €0.86.

Key valuation signals for STU:CNB1:

  • Cyclically Adjusted PS Ratio:
  • GF Value™: €0.86 vs. price of €1.93 (124.4% above fair value)
  • GF Score™: 45/100 with 6 warning signs

No single metric tells the full story. See the STU:CNB1 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fortress Biotech Business Description

Address 1111 Kane Concourse, Suite 301, Bay Harbor Island, FL, USA, 33154
Fortress Biotech Inc is a biopharmaceutical company. The firm is involved in the business of acquiring, developing, and commercializing pharmaceutical and biotechnology products. Its product portfolio encompasses Qbrexza, Accutane, Amzeeq, Zilxi, Targadox, and Exelderm. The business activities of the group are functioned through Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
45GF Score

Get the complete analysis for STU:CNB1

Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.93
Price
€0.86
GF Value